Profile | GDS2987 / GI_21361810-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 23.2 | 59 |
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | 24.2 | 58 |
GSM215254 | HMVEC_atorvastatin_rep1 | 28.7 | 57 |
GSM215282 | HMVEC_atorvastatin_rep3 | 20.4 | 43 |
GSM215344 | HMVEC_atorvastatin_rep2 | 10.5 | 26 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 23.1 | 41 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 16.5 | 32 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 3.3 | 6 |
GSM215294 | HMVEC_SLx2119_rep1 | 5.7 | 21 |
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 83.7 | 71 |
GSM215298 | PASMC_vehicle_rep2 | 79.5 | 70 |
GSM215310 | PASMC_vehicle_rep3 | 43.2 | 56 |
GSM215311 | PASMC_atorvastatin_rep1 | 23.4 | 38 |
GSM215312 | PASMC_atorvastatin_rep2 | 46.1 | 57 |
GSM215313 | PASMC_atorvastatin_rep3 | 39.6 | 51 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 46 | 59 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 35.6 | 55 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 76.7 | 71 |
GSM215327 | PASMC_SLx2119_rep1 | 39.6 | 55 |
GSM215328 | PASMC_SLx2119_rep2 | 28.9 | 47 |
GSM215329 | PASMC_SLx2119_rep3 | 4.4 | 9 |
GSM215330 | Fibroblasts_vehicle_rep1 | 59.2 | 69 |
GSM215331 | Fibroblasts_vehicle_rep2 | 44.3 | 66 |
GSM215332 | Fibroblasts_vehicle_rep3 | 51.6 | 69 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 55.6 | 70 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 51 | 69 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 69.6 | 71 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 65 | 72 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 69.2 | 72 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 77.9 | 73 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 33.4 | 63 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 46.4 | 68 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 44.4 | 66 |